Literature DB >> 11050267

Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis.

K Tsukamoto1, H Hayakawa, A Sato, K Chida, H Nakamura, K Miura.   

Abstract

BACKGROUND: The role of Epstein-Barr virus (EBV) in idiopathic pulmonary fibrosis (IPF) is uncertain. A study was undertaken to detect the virus in IPF as well as to clarify the influence of EBV on the clinical features of the disease.
METHODS: Twenty nine lung specimens were obtained from patients with IPF, as well as five specimens from patients with systemic sclerosis with pulmonary fibrosis (SSc) and 15 specimens from controls. EBV DNA and EBV latent membrane protein 1 (LMP1) were detected using the PCR method and immunohistochemical analysis, respectively.
RESULTS: EBV DNA was detected in 24 of 25 patients with IPF (96%), in all five patients with SSc (100%), and in 10 of 14 controls (71%). The detection ratio was significantly higher in patients with IPF than in controls (p = 0.047, odds ratio (OR) = 9.60, 95% confidence interval (CI) 0.9 to 96.9). Immunohistochemical analysis revealed that cuboidal epithelial cells were positively stained with anti-LMP1 antibody in nine of the 29 lung specimens from IPF patients. In contrast, neither the patients with SSc nor the control subjects showed positive staining. In the follow up periods LMP1 positive patients with IPF died more frequently from respiratory failure than LMP1 negative patients (4/9 versus 1/20; p = 0.022, OR = 15.20, 95% CI 1. 3 to 168.0).
CONCLUSIONS: EBV LMP1 positivity may be associated with more rapid disease progression in IPF.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11050267      PMCID: PMC1745627          DOI: 10.1136/thorax.55.11.958

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  29 in total

1.  Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus.

Authors:  D Liebowitz; D Wang; E Kieff
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

2.  An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells.

Authors:  D Wang; D Liebowitz; E Kieff
Journal:  Cell       Date:  1985-12       Impact factor: 41.582

3.  A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis.

Authors:  L C Watters; T E King; M I Schwarz; J A Waldron; R E Stanford; R M Cherniack
Journal:  Am Rev Respir Dis       Date:  1986-01

4.  Evidence that respiratory tract is major reservoir for Epstein-Barr virus.

Authors:  M L Lung; W K Lam; S Y So; W P Lam; K H Chan; M H Ng
Journal:  Lancet       Date:  1985-04-20       Impact factor: 79.321

Review 5.  Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract.

Authors:  R G Crystal; P B Bitterman; S I Rennard; A J Hance; B A Keogh
Journal:  N Engl J Med       Date:  1984-01-26       Impact factor: 91.245

6.  Natural history and treated course of usual and desquamative interstitial pneumonia.

Authors:  C B Carrington; E A Gaensler; R E Coutu; M X FitzGerald; R G Gupta
Journal:  N Engl J Med       Date:  1978-04-13       Impact factor: 91.245

7.  The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis.

Authors:  J P Stewart; J J Egan; A J Ross; B G Kelly; S S Lok; P S Hasleton; A A Woodcock
Journal:  Am J Respir Crit Care Med       Date:  1999-04       Impact factor: 21.405

8.  Opportunistic lymphoproliferations associated with Epstein-Barr viral DNA in infants and children with AIDS.

Authors:  W A Andiman; R Eastman; K Martin; B Z Katz; A Rubinstein; J Pitt; S Pahwa; G Miller
Journal:  Lancet       Date:  1985 Dec 21-28       Impact factor: 79.321

Review 9.  Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects.

Authors:  R G Crystal; J D Fulmer; W C Roberts; M L Moss; B R Line; H Y Reynolds
Journal:  Ann Intern Med       Date:  1976-12       Impact factor: 25.391

10.  Cryptogenic fibrosing alveolitis and Epstein-Barr virus: an association?

Authors:  J M Vergnon; M Vincent; G de Thé; J F Mornex; P Weynants; J Brune
Journal:  Lancet       Date:  1984-10-06       Impact factor: 79.321

View more
  32 in total

Review 1.  Idiopathic pulmonary fibrosis-an epidemiological and pathological review.

Authors:  Andrea T Borchers; Christopher Chang; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

Review 2.  Acute exacerbations of idiopathic pulmonary fibrosis.

Authors:  Harold R Collard; Bethany B Moore; Kevin R Flaherty; Kevin K Brown; Robert J Kaner; Talmadge E King; Joseph A Lasky; James E Loyd; Imre Noth; Mitchell A Olman; Ganesh Raghu; Jesse Roman; Jay H Ryu; David A Zisman; Gary W Hunninghake; Thomas V Colby; Jim J Egan; David M Hansell; Takeshi Johkoh; Naftali Kaminski; Dong Soon Kim; Yasuhiro Kondoh; David A Lynch; Joachim Müller-Quernheim; Jeffrey L Myers; Andrew G Nicholson; Moisés Selman; Galen B Toews; Athol U Wells; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2007-06-21       Impact factor: 21.405

3.  Fusion of epithelial cells by Epstein-Barr virus proteins is triggered by binding of viral glycoproteins gHgL to integrins alphavbeta6 or alphavbeta8.

Authors:  Liudmila S Chesnokova; Stephen L Nishimura; Lindsey M Hutt-Fletcher
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-17       Impact factor: 11.205

4.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

Review 5.  Viral infection and aging as cofactors for the development of pulmonary fibrosis.

Authors:  Payal K Naik; Bethany B Moore
Journal:  Expert Rev Respir Med       Date:  2010-12       Impact factor: 3.772

6.  Latent herpesvirus infection augments experimental pulmonary fibrosis.

Authors:  Kevin M Vannella; Tracy R Luckhardt; Carol A Wilke; Linda F van Dyk; Galen B Toews; Bethany B Moore
Journal:  Am J Respir Crit Care Med       Date:  2009-12-10       Impact factor: 21.405

Review 7.  Animal models of fibrotic lung disease.

Authors:  Bethany B Moore; William E Lawson; Tim D Oury; Thomas H Sisson; Krishnan Raghavendran; Cory M Hogaboam
Journal:  Am J Respir Cell Mol Biol       Date:  2013-08       Impact factor: 6.914

8.  Investigation of Toll-like receptors in the pathogenesis of fibrotic and granulomatous disorders: a bronchoalveolar lavage study.

Authors:  Giorgos A Margaritopoulos; Katerina M Antoniou; Kostas Karagiannis; Katerina D Samara; Ismini Lasithiotaki; Evi Vassalou; Rena Lymbouridou; Helen Koutala; Nikos M Siafakas
Journal:  Fibrogenesis Tissue Repair       Date:  2010-10-11

Review 9.  Viruses in Idiopathic Pulmonary Fibrosis. Etiology and Exacerbation.

Authors:  Bethany B Moore; Thomas A Moore
Journal:  Ann Am Thorac Soc       Date:  2015-11

10.  Twist: a regulator of epithelial-mesenchymal transition in lung fibrosis.

Authors:  Veronika Pozharskaya; Edilson Torres-González; Mauricio Rojas; Anthony Gal; Minal Amin; Sheila Dollard; Jesse Roman; Arlene A Stecenko; Ana L Mora
Journal:  PLoS One       Date:  2009-10-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.